AngioDynamics, Inc. $ANGO Stock Sold by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,921,526 shares of the medical instruments supplier’s stock after selling 48,309 shares during the period. Royce & Associates LP’s holdings in AngioDynamics were worth $29,553,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ANGO. Russell Investments Group Ltd. increased its position in shares of AngioDynamics by 7.0% during the third quarter. Russell Investments Group Ltd. now owns 75,085 shares of the medical instruments supplier’s stock worth $1,155,000 after acquiring an additional 4,895 shares in the last quarter. State of Wyoming lifted its position in AngioDynamics by 166.6% in the 3rd quarter. State of Wyoming now owns 14,750 shares of the medical instruments supplier’s stock valued at $227,000 after acquiring an additional 9,217 shares in the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in AngioDynamics in the 3rd quarter valued at $40,000. Integrated Wealth Concepts LLC bought a new stake in AngioDynamics in the 2nd quarter valued at $38,000. Finally, Corient Private Wealth LP acquired a new position in AngioDynamics in the 2nd quarter worth $134,000. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Down 0.9%

Shares of NASDAQ ANGO traded down $0.11 during midday trading on Friday, reaching $11.87. The company’s stock had a trading volume of 280,801 shares, compared to its average volume of 641,074. The stock has a 50 day simple moving average of $13.42 and a 200-day simple moving average of $12.54. The stock has a market capitalization of $499.13 million, a price-to-earnings ratio of -15.22 and a beta of 0.30. AngioDynamics, Inc. has a fifty-two week low of $9.39 and a fifty-two week high of $16.29.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. The business had revenue of $80.92 million during the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities analysts anticipate that AngioDynamics, Inc. will post -0.27 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. HC Wainwright cut their price target on AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a research report on Friday, October 9th. Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Insider Buying and Selling

In other AngioDynamics news, CFO Stephen Trowbridge sold 23,615 shares of the business’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $12.27, for a total transaction of $289,756.05. Following the sale, the chief financial officer directly owned 280,461 shares of the company’s stock, valued at $3,441,256.47. The trade was a 7.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 6.00% of the stock is owned by company insiders.

AngioDynamics Profile

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.